两种他汀类药物治疗早发冠心病急性心肌梗死的临床效果

The Clinical Effect of Two Statins in the Treatment of Premature Coronary Heart Disease and Acute Myocardial Infarction

目的研究分析两种他汀类药物治疗早发冠心病急性心肌梗死的临床效果。方法在该院2017年7月—2019年5月接诊早发冠心病患者中随机选取80例为研究对象,以就诊单双号分配患者于常规组和研究组,治疗分别采用阿托伐他汀和瑞舒伐他汀进行为期6个月的临床治疗,治疗后比较两组患者总胆固醇、三酰甘油等临床指标及用药不良反应发生概率。结果研究组患者采用瑞舒伐他汀治疗后,总胆固醇(3.24±0.13)mmol/L、三酰甘油(1.12±0.75)mmol/L、心肌肌钙蛋白(1.65±0.03)μg/L、肿瘤坏死因子(3.47±1.36)μg/L临床指标数据均优于常规组患者总胆固醇(3.91±0.24)mmol/L、三酰甘油(1.57±0.62)mmol/L、心肌肌钙蛋白(2.74±0.21)μg/L、肿瘤坏死因子(5.49±2.62)μg/L差异有统计学意义(P<0.05);研究组治疗用药后,恶心、口干、腹泻、疲乏嗜睡等用药不良反应发生概率为10.00%(4/40)明显低于常规组患者用药不良反应发生概率47.50%(19/40),差异有统计学意义(χ^(2)=13.730,P<0.05)。结论他汀类药物中阿托伐他汀和瑞舒伐他汀均能够对早发冠心病急性心肌梗死起到治疗作用,但瑞舒伐他汀在治疗效果、用药安全性上明显优于阿托伐他汀,因此以瑞舒伐他汀治疗效果更为良好,临床用药价值更高。

Objective To study and analyze the clinical effect of two kinds of statins in the treatment of early-onset coronary heart disease and acute myocardial infarction.Methods 80 patients with early-onset coronary heart disease in the hospital from July 2017 to May 2019 were randomly selected as the research object,and the patients were assigned to the conventional group and the study group by the even number of the treatment list.Atorvastatin and rosuvastatin were respectively used for 6 months of clinical treatment.After treatment,the two groups of patients were compared with clinical indicators such as total cholesterol,triglycerides and the incidence of side effects.Results After the study group was treated with rosuvastatin,total cholesterol(3.24±0.13)mmol/L,triglycerides(1.12±0.75)mmol/L,cardiac troponin(1.65±0.03)μg/L,tumor necrosis factor(3.47±1.36)μg/L and other clinical index data are better than those in the routine group,total cholesterol(3.91±0.24)mmol/L,triglycerides(1.57±0.62)mmol/L,cardiac troponin(2.74±0.21)μg/L,tumor necrosis factor(5.49±2.62)μg/L,the difference was statistically significant(P<0.05);After treatment and medication in the study group,the incidence of side effects such as nausea,dry mouth,diarrhea,fatigue and drowsiness was 10.00%(4/40),which was significantly lower than the incidence of side effects in the conventional group 47.50%(19/40),the difference was statistically significant(χ^(2)=13.730,P<0.05).Conclusion Atorvastatin and rosuvastatin can play a therapeutic role in the treatment of early-onset coronary heart disease acute myocardial infarction,but rosuvastatin is significantly better than atorvastatin in the treatment effect and medication safety,so rosuvastatin has better therapeutic effect and higher clinical medication value.